- Home
- ROIV vs CFR Comparison
ROIV vs CFR Comparison
Compare ROIV & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CFR
- Stock Information
- Founded
- ROIV 2014
- CFR 1868
- Country
- ROIV United Kingdom
- CFR United States
- Employees
- ROIV N/A
- CFR N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CFR Major Banks
- Sector
- ROIV Health Care
- CFR Finance
- Exchange
- ROIV Nasdaq
- CFR Nasdaq
- Market Cap
- ROIV 8.6B
- CFR 8.0B
- IPO Year
- ROIV N/A
- CFR N/A
- Fundamental
- Price
- ROIV $15.09
- CFR $127.45
- Analyst Decision
- ROIV Strong Buy
- CFR Hold
- Analyst Count
- ROIV 9
- CFR 16
- Target Price
- ROIV $19.94
- CFR $136.50
- AVG Volume (30 Days)
- ROIV 8.2M
- CFR 423.8K
- Earning Date
- ROIV 11-11-2025
- CFR 10-30-2025
- Dividend Yield
- ROIV N/A
- CFR 3.12%
- EPS Growth
- ROIV N/A
- CFR 13.33
- EPS
- ROIV N/A
- CFR 9.29
- Revenue
- ROIV $23,233,000.00
- CFR $2,079,741,000.00
- Revenue This Year
- ROIV N/A
- CFR $13.32
- Revenue Next Year
- ROIV $248.22
- CFR $4.15
- P/E Ratio
- ROIV N/A
- CFR $13.82
- Revenue Growth
- ROIV N/A
- CFR 6.87
- 52 Week Low
- ROIV $8.73
- CFR $100.31
- 52 Week High
- ROIV $16.05
- CFR $147.64
- Technical
- Relative Strength Index (RSI)
- ROIV 78.02
- CFR 46.85
- Support Level
- ROIV $13.81
- CFR $126.62
- Resistance Level
- ROIV $16.05
- CFR $128.13
- Average True Range (ATR)
- ROIV 0.50
- CFR 2.16
- MACD
- ROIV 0.22
- CFR -0.14
- Stochastic Oscillator
- ROIV 77.14
- CFR 27.52
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.